New data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy
2023-06-30 · Ionis Pharmaceuticals · original ionis.com ↗
Interim results from RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma® (onasemnogene abeparvovec) CARLSBAD, Calif., June 30, 2023 /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that its partner Biogen presented new data highlighting the potential benefit of SPINRAZA® (nusinersen) in infants and toddlers living with spinal muscular atrophy (SMA). Interim results from the RESPOND study showed improved motor function in most participants treated with SPINRAZA following treatment with Zolgensma® (onasemnogene abeparvovec). The data were presented today at the SMA Research & Clinical Care Meeting hosted by Cure SMA.
The release as fetched from its publisher. ionis.com ↗